Madrigal's MGL-3196 shows sustained benefit in mid-stage NASH study; shares up 40% premarket

May 31, 2018 7:19 AM ETMadrigal Pharmaceuticals, Inc. (MDGL)By: Douglas W. House, SA News Editor10 Comments
  • A Phase 2 clinical trial assessing Madrigal Pharmaceuticals' (NASDAQ:MDGL) MGL-3196 in patients with non-alcoholic steatohepatitis (NASH) met the primary endpoint at week 12 and demonstrated a sustained treatment benefit at week 36.
  • 39% of the responders at week 12 experienced complete resolution of NASH at week 36 compared to 6% for placebo (p=0.001). Fibrosis was resolved in half the patients.
  • Mean liver fat reduction was 37.0% in the treatment group compared to 8.9% for placebo.
  • No new safety signals were observed.
  • A larger Phase 3 with a longer treatment period is next up.
  • Management will host a conference call this morning at 8:30 am ET to discuss the results.
  • Shares are up 40% premarket on light volume.
  • Previously: Madrigal Pharma's lead candidate successful in mid-stage NASH study; shares ahead 45% premarket (Dec. 6, 2017)
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.